US2010160230A1PendingUtilityA1
Ubiquitin and ubiquitin related molecules for treatment and prevention of harmful activation of the immune system
Est. expiryAug 21, 2022(expired)· nominal 20-yr term from priority
A61P 43/00A61P 9/14A61K 38/16A61P 11/00
47
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Compositions and methods for suppressing the immune system of a mammal using ubiquitin and derivatives and analogs thereof.
Claims
exact text as granted — not AI-modified1 . A method of treating or preventing a disease, sequelae or pathological condition mediated by an activation of the immune system in a mammal comprising administering to said mammal an effective amount of ubiquitin, or a fragment, analog or derivative thereof.
2 . The method of claim 1 wherein ubiquitin is administered.
3 . The method of claim 1 wherein the pathological condition is capillary leakage.
4 . The method of claim 1 wherein the pathological condition is pulmonary failure.
5 . The method of claim 1 wherein the pathological condition is endotoxic shock.
6 . The method of claim 1 wherein the amount is between 0.01 and 10 mg/kg body weight.
7 . A method of inducing immunosuppression in a mammal comprising administering to said mammal an effective amount of ubiquitin, or a fragment, analog or derivative thereof.
8 . A method of treating or preventing sepsis in a mammal comprising administering to said mammal an effective amount of ubiquitin, or a fragment, analog or derivative thereof.
9 - 16 . (canceled)
17 . The method of claim 7 wherein ubiquitin is administered.
18 . The method of claim 7 wherein the amount is between 0.01 and 10 mg/kg body weight.
19 . The method of claim 8 wherein ubiquitin is administered.
20 . The method of claim 8 wherein the amount is between 0.01 and 10 mg/kg body weight.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.